Optimising management with personalised medicine

Personalised medicine looks at characteristics beyond the lungs

personalised-medicine personalised-medicine

Personalised medicine reinforces many existing elements of good clinical practice

good-clinical-practice good-clinical-practice

Personalised medicine empowers HCPs to deliver optimal care as early as possible in the treatment paradigm

empowers-HCPs empowers-HCPs

By focusing on important traits, the approach provides focus, rationale
and a systematic approach for simplicity in primary care

  • Personalised medicine is a label-agnostic, personalised approach to the assessment and treatment of airways disease, including asthma1,3
  • It is a model of care in which targeted management is aligned with the underlying disease in each individual, not only the traditional diagnostic label1,3
  •  Key traits should be clinically relevant; identifiable and measurable; and treatable7
  •  Key traits are identified and measured by a multidimensional assessment to create and implement an individualised management plan7
  •  Ongoing follow-up and evaluation are important, because traits may change with time, either as part of the disease course of as a result of treatment8
  • Personalised medicine reinforces many existing elements of good clinical practice. It provides a systematic assessment of a patients’ symptoms and comorbidities, allowing for a more comprehensive assessment than unstructured evaluations7,8

Examples of patient traits commonly encountered in primary care

examples-of-patient-traits examples-of-patient-traits

Footnote

†Also by FeNO in exhaled breath, but may not be available in primary care. Sputum eosinophil count can also be used but may be impractical for ongoing monitoring. Blood eosinophils are an effective marker.1,4

Abbreviations

BMI, body mass index; CBT, cognitive behavioural therapy; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids; 
LABA, long-acting β2-agonist; SABA, short-acting beta2-agonist
HCP, healthcare professional

 

Reference

1. Agusti A et al. Eur Respir J. 2016;47:410-9;

2 .Fingleton J et al. Curr Opin Pulm Med. 2018;24:24-31;

3. McDonald VM et al. Eur Respir J. 2019;53:1802058;

3A. McDonald VM et al. Respirology. 2019;24:37-47;

4. Shrimanker R et al. Clin Sci (Lond). 2017;131:1027-43.

5. Agusti A et al. Respir Med. 2021;187:106572;

6. Clark VL et al. Respirology. 2017;22:1262-75;

7. Agustí A et al. J Allergy Clin Immunol. 2023;11:713-723;

8. McDonald VM et al. ERJ Open Res. 2022;8:00215-2022.

9. GINA. 2023 Report. www.ginasthma.org. Accessed December 2023;

10. Yancey SW et al. J Allergy Clin Immunol. 2017;140:1509-18;

11. Freitas PD et al. Eur Respir J. 2021;57:2000240;

12. Tay TR and Hew M. Allergy. 2018;73:1369-82;

13. BTS/SIGN Guidelines. 2019. www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/. Accessed December 2023;

14. Dragomir AI et al. Transl Behav Med. 2021;11:642-52;

15.Blakey JD et al. Eur Respir J. 2018;52:1801147.

GSK is not responsible for third party links.

NX-KE-ASU-WCNT-240004 | October 2024